Disease Detail

Profile Responses 1
Clinical Trials 29

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Molecular Profile	Therapy	Indication/Tumor Type	Response Type	Profile Response Detail
PIK3CA H1047R	Everolimus	progesterone-receptor positive breast cancer	predicted - sensitive	detail...

Showing 1 to 1 of 1 entries

Filter rows:

Showing 1 to 29 of 29 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT01872260	Phase I	Alpelisib + Letrozole Alpelisib + Letrozole + Ribociclib Letrozole + Ribociclib	Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP \| CHE \| AUS	1
NCT02115282	Phase III	Exemestane + Goserelin Entinostat + Exemestane + Goserelin	Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic	Active, not recruiting	USA	1
NCT02918084	Phase III	Exemestane Anastrozole Letrozole	CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer (GIM10-CONSENT)	Active, not recruiting	ITA	0
NCT04478279	Phase Ib/II	ST-101	A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors	Active, not recruiting	USA \| GBR	0
NCT00570323	Phase II	Anastrozole + Fulvestrant Anastrozole	Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer	Completed	USA	0
NCT01177397	Phase Ib/II	Onatasertib	Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma	Completed	USA \| GBR \| FRA \| ESP	0
NCT01857193	Phase Ib/II	Everolimus + Exemestane + Ribociclib Exemestane + Ribociclib	Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer	Completed	USA \| FRA \| ESP \| BEL	1
NCT01990209	Phase II	Orteronel	Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)	Completed	USA	0
NCT02035813	Phase II	Ribociclib Eribulin	DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).	Completed	DEU	0
NCT04789668	Phase Ib/II	Bintrafusp alfa + Pimasertib	Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases	Completed	USA	0
NCT05538572	Phase I	PRT3645	A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors	Completed	USA	1
NCT05642949	Phase Ib/II	MHB036C	Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors	Not yet recruiting	AUS	0
NCT06224673	Phase II	ARX-788	ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer	Not yet recruiting	USA	0
NCT06680596	Phase II	Trastuzumab deruxtecan	Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy (SAFIR3LibHERty)	Not yet recruiting	FRA	0
NCT04305834	Phase II	Abemaciclib	Abemaciclib Monotherapy in Treating Older Patients With Hormone Receptor Positive Metastatic Breast Cancer	Recruiting	USA	0
NCT04557449	Phase I	Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060	Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i)	Recruiting	USA \| SVK \| GBR \| CZE \| ARG	3
NCT04706962	Phase I	TH1902	TH1902 in Patients With Advanced Solid Tumors	Recruiting	USA \| CAN	0
NCT05565417	Phase Ib/II	IMT-009	Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas	Recruiting	USA	0
NCT05627960	Phase I	AG01	First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies	Recruiting	USA	0
NCT05720117	Phase I	PYX-201	Study of PYX-201 in Solid Tumors	Recruiting	USA \| ESP \| BEL	0
NCT06018337	Phase III	Nab-paclitaxel Paclitaxel DB-1303 Capecitabine	A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)	Recruiting	USA \| POL \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS \| ARG	3
NCT06263543	Phase II	Sacituzumab govitecan-hziy	Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC (SERIES)	Recruiting	USA	0
NCT06545331	Phase I	Pembrolizumab + XB010 XB010	Study of XB010 in Subjects With Solid Tumors	Recruiting	USA	0
NCT00759642	Phase II	Lapatinib	Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy	Terminated	USA	0
NCT03330405	Phase II	Avelumab + Talazoparib	Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors	Terminated	USA \| HUN \| GBR \| DNK \| CAN \| BEL \| AUS	2
NCT04197999	Phase I	GMI-1359	A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer	Terminated	USA	0
NCT04256941	Phase II	Abemaciclib + Fulvestrant Fulvestrant + Palbociclib Letrozole + Palbociclib Fulvestrant + Ribociclib Abemaciclib + Letrozole Anastrozole + Palbociclib Anastrozole + Ribociclib Letrozole + Ribociclib Abemaciclib + Anastrozole	Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study	Terminated	USA	0
NCT04682431	Phase I	Pembrolizumab + PY159 PY159	A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Terminated	USA	0
NCT04054752	Phase I	NT-I7	Vaccine Response With NT-I7	Withdrawn	USA	0

Showing 1 to 29 of 29 entries

Filter rows:

ID	DOID:60077
Name	progesterone-receptor positive breast cancer
Definition	A breast cancer that is characterized by the presence of progesterone receptors.
Source	DiseaseOntology.org
Alt Ids
Path	disease disease of cellular proliferation cancer organ system cancer breast cancer progesterone-receptor positive breast cancer

Disease Detail

Contact

Filtering

Sorting